AR099330A1 - Uso de paricalcitol en el tratamiento de la anemia inflamatoria - Google Patents
Uso de paricalcitol en el tratamiento de la anemia inflamatoriaInfo
- Publication number
- AR099330A1 AR099330A1 ARP150100380A ARP150100380A AR099330A1 AR 099330 A1 AR099330 A1 AR 099330A1 AR P150100380 A ARP150100380 A AR P150100380A AR P150100380 A ARP150100380 A AR P150100380A AR 099330 A1 AR099330 A1 AR 099330A1
- Authority
- AR
- Argentina
- Prior art keywords
- paricalcitol
- erythropoiesis stimulating
- epoetin
- pharmaceutical composition
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Reivindicación 1: Uso de paricalcitol para la elaboración de una composición farmacéutica para el tratamiento de la anemia inflamatoria, en la que la dosis de paricalcitol a administrar está comprendida entre 5 - 10 mg/semana. Reivindicación 7: Composición farmacéutica que comprende paricalcitol administrado a una dosis comprendida entre 5 - 10 mg/semana, en combinación con al menos un agente estimulador de la eritropoyesis y junto con vehículos o excipientes farmacéuticamente aceptables. Reivindicación 10: Composición farmacéutica según las reivindicaciones 7 - 9 donde el agente estimulador de la eritropoyesis se selecciona de entre: EPO, agentes estimuladores de la eritropoyesis de primera generación seleccionados de entre cualquiera de los siguientes: epoetina a, epoetina b y epoetina d; agentes estimuladores de la eritropoyesis de segunda generación y/o agentes estimuladores de la eritropoyesis de tercera generación. Reivindicación 11: Composición farmacéutica según cualquiera de las reivindicaciones 7 - 10 donde el agente estimulador de la eritropoyesis es: EPO, Epoetina b, Neorecormón, Dynepo, Darbepoetina a y/o CERA.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES201430177A ES2472040B1 (es) | 2014-02-11 | 2014-02-11 | Uso de paricalcitol en el tratamiento de la anemia inflamatoria |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR099330A1 true AR099330A1 (es) | 2016-07-13 |
Family
ID=51205045
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150100380A AR099330A1 (es) | 2014-02-11 | 2015-02-10 | Uso de paricalcitol en el tratamiento de la anemia inflamatoria |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US11464791B2 (es) |
| EP (1) | EP3104872B1 (es) |
| JP (1) | JP2017512753A (es) |
| KR (1) | KR20160113664A (es) |
| CN (1) | CN106061498B (es) |
| AR (1) | AR099330A1 (es) |
| AU (1) | AU2015217956B2 (es) |
| CA (1) | CA2938057A1 (es) |
| DK (1) | DK3104872T3 (es) |
| ES (2) | ES2472040B1 (es) |
| IL (1) | IL247207B (es) |
| MX (1) | MX365096B (es) |
| PT (1) | PT3104872T (es) |
| RU (1) | RU2016131412A (es) |
| UY (1) | UY35989A (es) |
| WO (1) | WO2015121022A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022030665A1 (ko) * | 2020-08-05 | 2022-02-10 | 경상대학교병원 | 조영제-유발 신독성 예방 또는 치료용 약학 조성물 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004062620A2 (en) * | 2003-01-13 | 2004-07-29 | Cedars-Sinai Medical Center | Paricalcitol as a chemotherapeutic agent |
| AU2005235794A1 (en) * | 2004-04-23 | 2005-11-03 | Cambridge Antibody Technology Limited | Erythropoietin protein variants |
| EP2101808A4 (en) * | 2007-01-10 | 2011-11-30 | Edison Pharmaceuticals Inc | TREATMENT OF BREATHLY TROUBLES USING COMPOUNDS OF ERYTHROPOIETIN OR THROMBOPOIETIN ACTIVITY |
| CN102772364B (zh) * | 2011-05-13 | 2015-12-02 | 重庆华邦制药有限公司 | 帕立骨化醇的脂肪乳及其制剂和制备方法 |
-
2014
- 2014-02-11 ES ES201430177A patent/ES2472040B1/es not_active Expired - Fee Related
-
2015
- 2015-01-16 AU AU2015217956A patent/AU2015217956B2/en active Active
- 2015-01-16 CN CN201580007824.4A patent/CN106061498B/zh active Active
- 2015-01-16 RU RU2016131412A patent/RU2016131412A/ru unknown
- 2015-01-16 KR KR1020167023202A patent/KR20160113664A/ko not_active Application Discontinuation
- 2015-01-16 MX MX2016010104A patent/MX365096B/es active IP Right Grant
- 2015-01-16 EP EP15702156.9A patent/EP3104872B1/en active Active
- 2015-01-16 PT PT15702156T patent/PT3104872T/pt unknown
- 2015-01-16 WO PCT/EP2015/050817 patent/WO2015121022A1/en active Application Filing
- 2015-01-16 CA CA2938057A patent/CA2938057A1/en not_active Abandoned
- 2015-01-16 DK DK15702156.9T patent/DK3104872T3/da active
- 2015-01-16 ES ES15702156T patent/ES2728158T3/es active Active
- 2015-01-16 US US15/117,896 patent/US11464791B2/en active Active
- 2015-01-16 JP JP2016552329A patent/JP2017512753A/ja active Pending
- 2015-02-10 UY UY35989A patent/UY35989A/es not_active Application Discontinuation
- 2015-02-10 AR ARP150100380A patent/AR099330A1/es unknown
-
2016
- 2016-08-10 IL IL247207A patent/IL247207B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| UY35989A (es) | 2015-03-27 |
| DK3104872T3 (da) | 2019-06-17 |
| PT3104872T (pt) | 2019-06-11 |
| MX2016010104A (es) | 2017-01-06 |
| JP2017512753A (ja) | 2017-05-25 |
| IL247207A0 (en) | 2016-09-29 |
| CN106061498B (zh) | 2019-12-06 |
| EP3104872B1 (en) | 2019-03-13 |
| AU2015217956A1 (en) | 2016-08-25 |
| MX365096B (es) | 2019-05-22 |
| US20160367571A1 (en) | 2016-12-22 |
| CN106061498A (zh) | 2016-10-26 |
| KR20160113664A (ko) | 2016-09-30 |
| ES2472040R1 (es) | 2014-09-18 |
| IL247207B (en) | 2020-02-27 |
| ES2472040A2 (es) | 2014-06-27 |
| US11464791B2 (en) | 2022-10-11 |
| ES2472040B1 (es) | 2015-07-01 |
| ES2728158T3 (es) | 2019-10-22 |
| AU2015217956B2 (en) | 2019-04-04 |
| CA2938057A1 (en) | 2015-08-20 |
| EP3104872A1 (en) | 2016-12-21 |
| WO2015121022A1 (en) | 2015-08-20 |
| RU2016131412A (ru) | 2018-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019000938A2 (es) | Moduladores nmda espiro-lactam y métodos de uso de los mismos | |
| CO2019000945A2 (es) | Moduladores del receptor nmda espiro-lactam y uso de los mismos | |
| SV2017005461A (es) | Benzamidas sustituidas con 1,3-tiazol-2-ilo | |
| CO2019000944A2 (es) | Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos | |
| CO2019000941A2 (es) | Moduladores del receptor nmda espiro-lactam y uso de los mismos | |
| CO2019000943A2 (es) | Moduladores del receptor nmda espiro-lactam y uso de los mismos | |
| DOP2018000297A (es) | Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo | |
| MY196173A (en) | Cot Modulators And Methods Of Use Thereof | |
| CR20140365A (es) | Compuestos de carbamato y preparación y uso de los mismos | |
| AR088381A1 (es) | Formulaciones de etanercept estabilizadas con meglumina | |
| CL2015003072A1 (es) | Formulaciones de liberación prolongada de colchicina y métodos de uso de las mismas. | |
| AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
| MX2016008429A (es) | Derivado de piranocromenil fenol, y composicion farmaceutica para tratar un sindrome metabolico o enfermedad inflamatoria. | |
| CL2021002107A1 (es) | Triamtereno o nolatrexed para uso en el tratamiento de fenilcetonuria. | |
| AR115913A1 (es) | Formas de dosificación oral biodisponibles, uso, métodos | |
| ECSP19026973A (es) | Derivados de naftiridinona y su uso en el tratamiento de la arritmia | |
| AR102778A1 (es) | Composición farmacéutica, su preparación y sus usos | |
| AR102782A1 (es) | Composición farmacéutica, su preparación y sus usos | |
| CL2020000019A1 (es) | Agentes de iarn para la inhibición de la expresión de alfa-enac y métodos de uso. | |
| MX2019001771A (es) | Composición farmacéutica sólida que comprende el sofosbuvir amorfo. | |
| AR099330A1 (es) | Uso de paricalcitol en el tratamiento de la anemia inflamatoria | |
| BR112019022459A2 (pt) | Agente terapêutico para câncer no sangue | |
| AR110957A1 (es) | Agente terapéutico oral para tiroides | |
| DOP2019000233A (es) | Dropropizina en combinacion con ambroxol en la forma farmaceutica de jarabe y tableta | |
| UA113233U (uk) | Пероральна фіксована комбінація теноксикаму і снодійного або заспокійливого компонента |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |